KZIANasdaqPharmaceutical PreparationsFiscal year ends June 30
KAZIA THERAPEUTICS LTD
Financials through fiscal 2025, year ended Jun 30, 2025Last filing: 20-F on Nov 7, 2025
$7.85+0.60 (+8.28%)
Close on Oct 19, 2026
KAZIA THERAPEUTICS LTD revenue by segment
By business segment
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|
| Sale of paxalisib [Member] | A$42.00K | A$7.00K | A$0 | A$0 | – | 100.0% | +500.0% |
| Licensing revenue [Member] | A$0 | A$2.30M | A$0 | A$0 | A$15.18M | 0.0% | -100.0% |
By region
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|
| Israel | A$42.00K | A$0 | A$0 | – | – | 100.0% | – |
| KR [Member] | A$0 | A$2.31M | A$0 | A$0 | – | 0.0% | -100.0% |
| Swedan [member] | – | – | – | – | A$5.18M | – | – |
| China | – | – | A$0 | A$0 | A$10.01M | – | – |
| Sweden | – | – | A$0 | A$0 | A$5.18M | – | – |
From the segment and revenue-disaggregation notes of Kazia Therapeutics's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.